metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	atezolizumab alone vs. docetaxel	2	statistically conclusive 21 % decrease in deaths (OS) suggested 47 % decrease in AE (grade 3-4) suggested 55 % decrease in AE leading to treatment discontinuation (any grade) suggested 71 % decrease in TRAE (any grade) suggested 77 % decrease in TRAE (grade 3-4)	inconclusive results for: progression or deaths (PFS); DOR; objective responses (ORR); AE (any grade); AE leading to death (grade 5); SAE (any grade); SAE (grade 3-4); TRAE leading to death (grade 5); Alopecia AE (grade 3-4); Arthralgia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Cough AE (grade 3-4); Diarrhoea AE (grade 3-4); Dysgeusia AE (grade 3-4); Dyspnoea AE (grade 3-4); Fatigue AE (grade 3-4); Myalgia AE (grade 3-4); Nausea AE (grade 3-4); Peripheral neuropathy AE (grade 3-4); Peripheral oedema AE (grade 3-4); Pyrexia AE (grade 3-4); Vomiting AE (grade 3-4)	suggested 93 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable suggested 61 % decrease in Anaemia AE (grade 3-4) but the degree if certainty is unassessable suggested 79 % decrease in Decreased appetite AE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Febrile neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 97 % decrease in Neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 92 % decrease in Stomatitis AE (grade 3-4) but the degree if certainty is unassessable	-

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel